FW Pharma Systems announces proposed subscription service linking IMPACT and AcurianÂ’s Investigator Database
FW Pharma Systems, announce their intention to provide enhanced investigator management solutions for users of leading Clinical Trials Management System, IMPACT.
(PRWEB) June 28, 2002
“IMPACT has established itself as the leading CTMS and Acurian has developed the industry’s most comprehensive database of experienced clinical investigators,” says Paul Tebbs, Business Development Director, FW Pharma Systems. “It makes excellent sense for us to bring the two together, providing a link that enables IMPACT users to augment their own database of investigators by searching Acurian’s Investigator Database by speciality, prescribing behaviour, trial experience and other relevant metrics. IMPACT users will also be able to see the number of patients in Acurian’s Patient Database of more than 4.3 million individuals that are geographically proximate to selected investigator sites. These new search capabilities will be made available within our customers’ own secure IMPACT trials management environment and can be used to set up potential trial units. By incorporating the data within IMPACT, users benefit from using familiar routines, together with a smoother workflow process – no hot-keying between applications and no conversion of data formats required.”
“Access to our Investigator Database through IMPACT will provide sponsors with the relevant data they need to make informed decisions in regards to investigator recruitment,” said Mark Eisenach, CEO of Acurian. “By teaming with a market leader like FW Pharma Systems, we can quickly provide our informatics-based approach to investigator recruitment to multiple sponsors in an integrated, turnkey fashion.”
According to Tebbs, “Increasingly, both CROs and sponsors will need ready access to high-quality investigator and patient data to expedite study start-up. That is why FWPS is actively pursuing links between IMPACT and Acurian, to help jumpstart the investigator enrolment process. We plan to have integrated Acurian’s Investigator Database into IMPACT in time for the DIA’s Annual meeting in June in Chicago.”
About FW Pharma Systems
FW Pharma Systems is an independent, global company dedicated to providing business solutions to the clinical research sector.
IMPACT is the market leader in Clinical Trials Management Software. It is designed to assist pharmaceutical companies, CROs, device manufacturers and biotech companies in managing research activities - ranging in scale from single site to large multinational, multi site studies.
About Acurian
Acurian is a leading provider of clinical trial patient and investigator recruitment solutions for the pharmaceutical and biotechnology industries. Through customised data mining of proprietary databases, Acurian is able to identify, contact and prescreen interested patients, as well as profile and recruit experienced investigators, quickly and affordably. To date, Acurian has helped accelerate more than 60 clinical trials for 40 pharmaceutical and biotechnology companies, including the seven largest pharmaceutical companies in the world. With a seasoned management team, innovative technology solutions, a Safe Harbor certification to serve customers in Europe and more than $38 million in total funding from top technology and healthcare investors, including Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Sofinov, Flatiron Partners & Merck Capital Ventures, Acurian is poised for long-term success. Additional information about Acurian is available at www. acurian. com.
For further information contact:
Jo Gadd, Marketing Manager
FW Pharma Systems
E: info@fwpharma. com
David Restrepo,
Vice President, Marketing
Acurian
E: david. restrepo@acurian. com
